MX2022011409A - Vesiculas extracelulares de diseño para tratar la excitotoxicidad. - Google Patents

Vesiculas extracelulares de diseño para tratar la excitotoxicidad.

Info

Publication number
MX2022011409A
MX2022011409A MX2022011409A MX2022011409A MX2022011409A MX 2022011409 A MX2022011409 A MX 2022011409A MX 2022011409 A MX2022011409 A MX 2022011409A MX 2022011409 A MX2022011409 A MX 2022011409A MX 2022011409 A MX2022011409 A MX 2022011409A
Authority
MX
Mexico
Prior art keywords
excitotoxicity
glutamate
designer
cns
extracellular vesicles
Prior art date
Application number
MX2022011409A
Other languages
English (en)
Inventor
Daniel Gallego-Perez
Natalia Higuita-Castro
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of MX2022011409A publication Critical patent/MX2022011409A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

En la presente se divulgan vesículas extracelulares (EV) de diseño funcionalizadas con receptores de glutamato (por ejemplo, mGluR4 y mGluR8) que pueden dirigirse selectivamente a regiones lesionadas del SNC que experimentan excitotoxicidad; las EV decoradas con mGluR4 y mGluR8 se anclan preferentemente en áreas lesionadas del SNC con un marcado aumento en el glutamato extracelular asociado con neurotoxicidad y excitotoxicidad profusas; por lo tanto, la decoración con receptor de glutamato puede conducir a un mejor direccionamiento en áreas ricas en glutamato del SNC.
MX2022011409A 2020-03-17 2021-03-17 Vesiculas extracelulares de diseño para tratar la excitotoxicidad. MX2022011409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990783P 2020-03-17 2020-03-17
PCT/US2021/022674 WO2021188616A1 (en) 2020-03-17 2021-03-17 Designer extracellular vesicles for treating excitotoxicity

Publications (1)

Publication Number Publication Date
MX2022011409A true MX2022011409A (es) 2022-12-02

Family

ID=77771275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011409A MX2022011409A (es) 2020-03-17 2021-03-17 Vesiculas extracelulares de diseño para tratar la excitotoxicidad.

Country Status (11)

Country Link
US (1) US20230226118A1 (es)
EP (1) EP4121117B1 (es)
JP (1) JP2023518218A (es)
KR (1) KR20220154132A (es)
CN (1) CN115666655A (es)
AU (1) AU2021238317A1 (es)
BR (1) BR112022018395A2 (es)
CA (1) CA3175322A1 (es)
IL (1) IL296508A (es)
MX (1) MX2022011409A (es)
WO (1) WO2021188616A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4615418A1 (en) * 2022-11-10 2025-09-17 Ohio State Innovation Foundation Designer extracellular vesicles for targeted delivery to muscle cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4495174A (en) 1982-06-21 1985-01-22 Research Corporation Anesthetic polyorganophosphazenes
US4440921A (en) 1982-06-21 1984-04-03 Research Corporation Coupling of polyorganophosphazenes to carboxylic acid
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4880622A (en) 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP2983721B2 (en) 2013-04-12 2021-01-20 Evox Therapeutics Limited Therapeutic delivery vesicles
WO2016039356A1 (ja) * 2014-09-09 2016-03-17 森永乳業株式会社 抗炎症剤
LT3458053T (lt) * 2016-05-20 2022-02-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
EP3308795A1 (en) * 2016-10-12 2018-04-18 Unicyte EV AG A composition of extracellular vesicles (evs) and medical uses thereof
MX2019005127A (es) * 2016-11-03 2019-09-26 Exostem Biotec Ltd Poblaciones y productos de células madre mesenquimales y sus usos.
IL266652B2 (en) * 2016-11-16 2024-11-01 Nanosomix Inc Quantification of subpopulations of exosomes and diagnosis of neurodegenerative disorders
JP2020505342A (ja) * 2017-01-17 2020-02-20 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞
CN111133106A (zh) * 2017-07-12 2020-05-08 外来体诊断公司 用于分离和富集生物流体来源的细胞外囊泡的方法及其使用方法

Also Published As

Publication number Publication date
CN115666655A (zh) 2023-01-31
KR20220154132A (ko) 2022-11-21
EP4121117B1 (en) 2025-10-08
EP4121117A1 (en) 2023-01-25
JP2023518218A (ja) 2023-04-28
AU2021238317A1 (en) 2022-09-29
US20230226118A1 (en) 2023-07-20
CA3175322A1 (en) 2021-09-23
EP4121117A4 (en) 2024-04-17
IL296508A (en) 2022-11-01
WO2021188616A1 (en) 2021-09-23
BR112022018395A2 (pt) 2023-02-28

Similar Documents

Publication Publication Date Title
CO2020004233A2 (es) Vesículas extracelulares bacterianas
CY1126255T1 (el) Χρησεις ανταγωνιστων il-13 για την αγωγη της ατοπικης δερματιτιδας
CR20190375A (es) Anticuerpos anti-tgf-beta y su uso
MX2020010227A (es) Construcciones dirigidas a cd22 y usos de las mismas.
CY1123996T1 (el) Υποκατεστημενα παραγωγα οξοπυριδινης
CO2020009091A2 (es) Exosomas para inmunooncología y terapia antiinflamatoria
UY37269A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
CL2024002173A1 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteínas de las mismas
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
CA176339S (en) Gel cushion insole
UY38800A (es) Receptor de antígeno quimérico (car) anti-hk2
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
CO2018010827A2 (es) Anticuerpos anti-factor bb del complemento y usos de estos
CL2020001290A1 (es) Método para el tratamiento de enfermedades gastrointestinales con tradipitant.
CA176340S (en) Gel cushion insole
MX2022011409A (es) Vesiculas extracelulares de diseño para tratar la excitotoxicidad.
MX2022006132A (es) Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
BR112019006200A2 (pt) misturas para espumas, espumas fabricadas a partir das mesmas e artigos que compreendem as mesmas
MX2020010110A (es) Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
CO2024015383A2 (es) Agentes aglutinantes 5t4 y usos de los mismos
CL2024001542A1 (es) Métodos para utilizar agonistas de rar gamma para el tratamiento del cáncer
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.